Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1711 to 1725 of 1773 results for patient safety

  1. Biotin for treating primary and secondary progressive multiple sclerosis [ID919]

    Discontinued Reference number: GID-TA10099

    Technology appraisal guidance
    Discontinued

  2. Bulevirtide for treating chronic hepatitis D (TA896)

    Evidence-based recommendations on bulevirtide (Hepcludex) for chronic hepatitis D in adults.

    Technology appraisal guidance
    Published
    7 June 2023
    View recommendations

    Sections for TA896

  3. Digital technologies to support smoking cessation in secondary care patients: early value assessment

    In development Reference number: GID-HTE10061 Expected publication date: TBC

    Health technology evaluations
    In development

  4. Nivolumab with ipilimumab for untreated non-small-cell lung cancer that has a high tumour mutational burden [ID1187]

    Discontinued Reference number: GID-TA10234

    Technology appraisal guidance
    Discontinued

  5. Accuro for guiding epidural or spinal anaesthesia (MIB245)

    NICE has developed a medtech innovation briefing (MIB) on Accuro for guiding epidural or spinal anaesthesia .

    Medtech innovation briefing
    Published
    26 January 2021

  6. Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]

    Discontinued Reference number: GID-TA10764

    Technology appraisal guidance
    Discontinued

  7. Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain (MIB238)

    NICE has developed a medtech innovation briefing (MIB) on Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain .

    Medtech innovation briefing
    Published
    8 December 2020

  8. Air pollution: outdoor air quality and health (NG70)

    This guideline covers road-traffic-related air pollution and its links to ill health. It aims to improve air quality and so prevent a range of health conditions and deaths.

    NICE guideline
    Published
    30 June 2017
    View recommendations

    Sections for NG70

  9. Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]

    In development Reference number: GID-TA10900 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Pembrolizumab for untreated PD-L1 positive non-small-cell lung cancer with at least 1% tumour proportion score [ID1247]

    Discontinued Reference number: GID-TA10271

    Technology appraisal guidance
    Discontinued

  11. Atezolizumab in combination with platinum-based chemotherapy for untreated locally advanced or metastatic urothelial cancer [ID1206]

    Discontinued Reference number: GID-TA10202

    Technology appraisal guidance
    Discontinued

  12. What is the clinical and cost effectiveness of CBD in epileptic disorders in children, young people and adults?

    committee were aware from cases highlighted by stakeholders that individual patients have reported having fewer seizures with these...

    Research recommendation
    Published
    10 February 2020

  13. Does the addition of THC to CBD have an effect on seizure frequency, brain structure and neuropsychological performance when compared with both CBD alone and placebo in epileptic disorders in children, young people and adults?

    committee were aware from cases highlighted by stakeholders that individual patients have reported having fewer seizures with these...

    Research recommendation
    Published
    10 February 2020

  14. Non-bisphosphonates for treating osteoporosis [ID901]

    Discontinued Reference number: GID-TA10072

    Technology appraisal guidance
    Discontinued

  15. Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

    Discontinued Reference number: GID-HST10007

    Highly specialised technologies guidance
    Discontinued